Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Megan A Foley

Interventional Pain Medicine Ridgewood, NJ Physician Assistant

NPI 1356025894 CMS profile 11439295

1144 E Ridgewood Ave, Ridgewood, NJ 07450

Open in the dashboard

General payments

$1,362

48 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Megan A Foley of Ridgewood, NJ is reported in the CMS Open Payments database as having received $1,362 across 48 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 29th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $40 2
2024 General $1,174 40
2023 General $148 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Megan A Foley
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Megan A Foley were reported at $40. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Megan A Foley Interventional Pain Medicine median Middle half National median
2019 $0 $684 $216–$2,079 $163
2020 $0 $382 $122–$1,109 $114
2021 $0 $552 $167–$1,554 $132
2022 $0 $605 $187–$1,924 $149
2023 $148 $671 $195–$1,915 $160
2024 $1,174 $684 $206–$1,837 $164
2025 $40 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. BIOTRONIK NRO, Inc. $710 30 payments
  2. Vertos Medical, Inc. $431 14 payments
  3. Medtronic, Inc. $182 2 payments
  4. Boston Scientific Corporation $23 1 payment
  5. AbbVie, Inc. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $1,362 48 payments
Products named General payments · program years 2023–2025
  1. Prospera $562 24 payments
  2. mild Device Kit $431 14 payments
  3. INTELLIS ADAPTIVESTIM $182 2 payments
  4. BIOTRONIK $148 6 payments
  5. Intracept RF Probe $23 1 payment
  6. UBRELVY $18 1 payment
  7. QULIPTA $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

254

Median for Physician Assistant: 241

Drug cost

$432,426

Median for Physician Assistant: $4,110

Branded share of claims

28.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 12 $427,977
Oxycontin Oxycodone Hcl Brand 12 $3,297
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 48 $410
Pregabalin Generic 31 $241
Cyclobenzaprine Hcl Generic 40 $129
Gabapentin Generic 33 $123
Methylprednisolone Generic 16 $90
Tizanidine Hcl Generic 17 $77
Tramadol Hcl Generic 22 $50
Meloxicam Generic 23 $31

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$15,914

Of which drugs: $168

Medicare patients

65

Average age 72

Services billed

438

36 women, 29 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 35%
Ischemic heart disease 35%
Depression 34%
COPD 20%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 34 216 $168

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

48 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record